Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases
REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor...
Brain
GoMo Health Launches the Women, Children and Families Engagement Hub to Improve Whole-Family Care and Health Outcomes In Every Life Stage
Holistic engagement programs offer healthcare organizations a scalable solution to support women and families in managing their physical, mental, and...
BestQool Announces Summer Promotion and Fall Refresh with New Logo and BQ60Pro Preview
Summer Appreciation Sales Offers 12% Off All Products NEW YORK, Aug. 15, 2025 /PRNewswire/ -- BestQool , a pioneer manufacturer...
CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Strong cash position of $12.1 million expected to fund operations into the second half of 2026Driving lead program, TPI 287,...
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile Initial...
“I WISH I HAD THIS WHEN I WAS A KID,” MINDIFUL® MOVEMENT PUTS KIDS FIRST
The most magical part? It's for everyone. HOLLYWOOD, Calif., Aug. 14, 2025 /PRNewswire/ -- Mindiful® is leading a movement to...
Invictus Foundation™ Receives Grant from CSX to Install a Behavioral Telehealth Platform in its Southeastern Regional Welcome Home Network and Continue the Capital Construction Planning for Eight Regional TBI & Behavioral Health Centers Across the Nation
SEATTLE, Aug. 14, 2025 /PRNewswire/ -- To the Invictus Foundation, CSX's support represents the best of good corporate citizenship," states Peter...
CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
- Live video webcast on Tuesday, August 19th at 2:40 PM ET HOUSTON, TX / ACCESS Newswire / August 14,...
Hemostemix’s Expands its Marketing Team Focused on Sales in Florida
Calgary, Alberta--(Newsfile Corp. - August 14, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous stem cell...
Last patient visit completed on schedule in Phase 1b clinical trial of HER-096 for Parkinson’s disease
Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300...
Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights
Following constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its...
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability
WESTBROOK, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health...
Cassava Reports Q2 2025 Financials Results and Provides Business Update
Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the...
Parents Urged to Make Kids’ Bedtime Screen-Free as National Campaign Launches with NYC Flash Mob
"Screen-Free Sleep" movement takes to the streets to address America's youth sleep crisis NEW YORK, Aug. 14, 2025 /PRNewswire/ --...
Moleculin Reports Second Quarter 2025 Financial Results and Highlights
- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial- 20+ additional clinical sites in...
Moleculin Reports Second Quarter 2025 Financial Results and Highlights
- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial- 20+ additional clinical sites in...
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE...
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE...
Native Hydrate Reviews: Don’t Buy Until You’ve Read This!
NEW YORK, NY / ACCESS Newswire / August 12, 2025 / Forget everything you thought you knew about staying hydrated...